まとめ
乳児と小児は,成人よりも高い血清ディジトキシンレベルを耐受することができ,毒性はありません. これは,効果的な小児デジタルス療法と毒性の管理のために,調整された用量が必要になる可能性があることを示唆しています.
科学分野:
- 薬理学 薬理学とは
- 小児科は小児科です.
- 心臓病学 心臓病学
背景:
- ディジトキシンのようなディジタリス・グリコシドは,小児性心不全および心律不整症の管理に不可欠です.
- デジトキシンに対する年齢特有の治療範囲を理解することは,安全で効果的な治療のために不可欠です.
研究 の 目的:
- 維持療法を受けている乳児および小児の血清ディジトキシン濃度を,成人のレベルと比較する.
- 血清ディジトキシン濃度と小児集団における臨床毒性との関係を評価する.
主な方法:
- 血清のデジトキシン濃度は,維持療法を受けている18人の乳児と23人の小児で測定されました.
- 投与量,デジタル化の指示,および毒性の兆候が記録されました.
- 小児のレベルは,既定の成人レベルと比較されました.
主要な成果:
- 乳児 (30ng/ml) と小児 (34ng/ml) の平均血清ディジトキシン濃度は,それぞれ有意な差異はなかった.
- 小児の濃度は,大人の濃度 (24ng/ml) よりも著しく高かった.
- 毒性を示す患者は,血清ディジトキシン濃度 (71-72ng/ml) が著しく高かった.
結論:
- 乳児と小児は,成人よりも血清ディジトキシン濃度が高く耐えているようです.
- 小児患者は,治療効果のためにより高いmg/kgの投与が必要になる可能性があります.
- 血清デジタル毒素のモニタリングは,デジタル化の最適化と子供における毒性の管理に不可欠です.
関連する概念動画
01:15Determination of Multiple Dosing Parameters: Steady-State, Minimum and Maximum Concentrations
Gentamicin, an aminoglycoside antibiotic, is commonly administered via intermittent intravenous infusion to treat severe infections. An intermittent one-hour infusion of gentamicin, administered at eight-hour intervals, allows for precise control of plasma drug concentrations, minimizing toxicity while ensuring therapeutic efficacy. Pharmacokinetic principles govern the dynamics of plasma concentrations and can be mathematically described using specific equations.The plasma drug concentration...
01:29Drug Dosing: Infants and Children
Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
01:17Pharmacokinetics in Pediatric Patients: Drug Distribution
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
01:28Diphtheria
Diphtheria is an acute, toxin-mediated infectious disease that primarily affects the upper respiratory tract. It is caused by Corynebacterium diphtheriae, a Gram-positive, pleomorphic rod that lacks spore-forming capability and exhibits a characteristic club-shaped morphology under microscopic examination. While C. diphtheriae can asymptomatically colonize mucosal surfaces, clinical disease manifests only when the bacterial strain is lysogenized by a specific β-corynephage. This phage...